相关实验视频

Updated: Jan 10, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

[治疗腹占主导地位的刺激性肠综合征与缺陷和湿度保留:随机对照试验]

Xiao Mei¹, Wei Wang², Xiao-Fei Li¹

¹The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.

Zhen ci yan jiu = Acupuncture research

|November 19, 2025

概括

在Shenque (CV8) 应用针显著改善了腹占主导地位的刺激性肠综合征 (IBS-D) 和缺陷的患者的症状和便特征. 这种传统中医方法提供了安全有效的治疗选择.

科学领域:

胃肠病学胃肠病学
综合医学是一个整体的医学.
传统中国医药传统中国医药

背景情况:

腹占主导地位的刺激性肠综合征 (IBS-D) 伴有缺陷和湿度保留,带来了重大的临床挑战.
目前的治疗方法可能有局限性,需要探索替代治疗策略.

研究的目的:

评估Shenque (CV8) 针应用在IBS-D患者的临床疗效,这些患者患有缺陷和湿度保留.
为了比较针点应用与口服益生菌相结合的疗效,与单独的口服益生菌相比.

主要方法:

一项随机对照试验,涉及88名被诊断患有缺陷和湿度保留类型IBS-D的患者.
实验组在CV8接受了口服益生菌加针应用,而对照组仅接受了口服益生菌.
治疗持续时间为4周,评估包括传统中医 (TCM) 综合征得分,IBS严重程度量表 (IBS-SSS) 和IBS便特征问卷 (IBS-DSQ).

主要成果:

这两组治疗后的TCM综合征,IBS-SSS和IBS-DSQ得分均显著改善 (P<0.001).
与对照组相比,实验组在所有测量尺度 (P<0.01,P<0.05) 上表现出明显更大的改善.
具体来说,针点应用组显示腹,腹痛和胀气明显减少,总有效率为88.1%,对照组为73.8% (P<0.05).

结论:

在CV8的针点应用是IBS-D患者的安全和有效的辅助疗法,其中包括欠缺和保持湿度的患者.
这种治疗显著缓解了腹,腹痛和膨胀等关键症状,同时改善了便的一致性和整体生活质量.
这些发现支持对这种特定的IBS-D亚型进行针治疗的临床推广和应用.

关键词:

针点应用程序针点应用程序腹占主导地位的刺激性肠综合征.随机对照试验是随机对照试验.

更多相关视频

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...